Results 11 to 20 of about 2,069,003 (398)

Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH).
Su-Gang Gong   +9 more
doaj   +1 more source

Comparative Effectiveness of Exercise Training for Patients With Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) still experience reduced exercise capacity despite pulmonary endarterectomy (PEA). Exercise training improves the exercise capacity and quality of life (QoL) in patients with
Ya-Lin Zhao   +10 more
doaj   +1 more source

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial

open access: yesTrials, 2021
Background Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, riociguat, a soluble guanylate-cyclase stimulator is recommended by international guidelines.
Qin-Hua Zhao   +12 more
doaj   +1 more source

Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease

open access: yesBMC Cardiovascular Disorders, 2022
Background Pulmonary hypertension in left heart disease (PH-LHD), which includes combined post- and precapillary PH (Cpc-PH) and isolated postcapillary PH (Ipc-PH), differs significantly in prognosis.
Xiu-Jun Zhong   +13 more
doaj   +1 more source

CircGSAP alleviates pulmonary microvascular endothelial cells dysfunction in pulmonary hypertension via regulating miR-27a-3p/BMPR2 axis

open access: yesRespiratory Research, 2022
Background Our previous study showed that circular RNA-gamma-secretase-activating protein (circGSAP) was down-regulated in pulmonary microvascular endothelial cells (PMECs) in response to hypoxia, and regulated the cell cycle of PMECs via miR-942-5p ...
Yuanyuan Sun   +11 more
doaj   +1 more source

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

open access: yesFrontiers in Cardiovascular Medicine, 2022
BackgroundThere is little evidence of the effectiveness of switching from the endothelin receptor antagonists (ERAs) bosentan and ambrisentan to a novel ERA, macitentan, in patients with pulmonary arterial hypertension (PAH).
Jie Li   +14 more
doaj   +1 more source

A novel pulmonary circulation imaging using dynamic digital radiography for chronic thromboembolic pulmonary hypertension

open access: yesEuropean Heart Journal, 2020
A 46-year-old man with chronic thromboembolic pulmonary hypertension (CTEPH) was referred to our hospital to undergo pulmonary endarterectomy (PEA). Tc-99m MAA lung perfusion scintigraphy showed multiple perfusion defects in the bilateral lung field ...
Y. Yamasaki   +3 more
semanticscholar   +1 more source

Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism

open access: yesAnimal Models and Experimental Medicine, 2022
Circular RNAs (circRNAs) are endogenous RNAs with a covalently closed single‐stranded transcript. They are a novel class of genomic regulators that are linked to many important development and disease processes and are being pursued as clinical and ...
Qian Wang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy